Agency: Department of Agriculture | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 54.55K | Year: 1997
In soybean-based animal feeds, the two galacto-oligosaccharide (raffinose and stachyose) present majorobstacles in accessing the full nutritive value of the soybean meal portion of the diet by chickens andturkeys. The problem is caused by the inability of these animals to hydrolyze raffinose and stachyoseinto galactose and fructose using endogenous digestive enzymes. Consequently, soybean meal has alower metabolizable energy than would be expected based on a standard proximate analysis. With thecurrent emphasis on plant genetic engineering to develop high energy grain, and a trend towards agreater reliance on plant-based nutrition due to concerns over Bovine Spongioform Encephalitis (BSE),improving the total nutritional value of soybean is an important target from an animal productionperspective. To date, there are few examples of the use of supplemental enzymes for soybean-baseddiets. The proposed research program would initially be focused on optimizing the use of an?-galactosidase to enhance the nutritive value of soybean in turkeys. In parallel, a biochemical assaywill be developed to quantify the effect of an ?-galactosidase on the release of sucrose from raffinoseand stachyose in vitro and establish a close correlation between in vitro assay results and in vivo animaltrials.
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 50.00K | Year: 1991
TOMATO PLANTS, STABLY TRANSFORMED WITH A FUSED CAMV TOMATO INHIBITOR GENE LICENSED TO KEMIN INDUSTRIES, INC., FROM WASHINGTON STATE UNIVERSITY, WILL BE SCREENED FOR INDIVIDUAL LINES THAT PRODUCE VERY HIGH QUANTITIES OF ANTICARCINOGENIC PROTEASE INHIBITOR I IN THE UNRIPE FRUIT. HIGH YIELDING TRANSFORMANTS WILL BE CROSSED INTO COMMERCIALLY GROWN STRAINS. FRUITS FROM TRANSGENIC PLANTS POSSESSING HIGH LEVELS OF THE INHIBITOR WILL BE USED TO DESIGN AN ECONOMICALLY FEASIBLE PROCEDURE TO PROVIDE LOW COST INHIBITOR I FOR FURTHER STUDY IN ITS ROLE AS AN ANTICARCINOGENIC SUBSTANCE. IF LONG RANGE STUDIES DEMONSTRATE THE VALUE OF THE MATERIAL IN PREVENTING CANCER, PILOT AND, FINALLY, FULL SCALE PREPARATION PROCEDURES WILL BE UTILIZED TO PROVIDE PRODUCT TO THE MARKET. ACHIEVEMENT OF PHASE I OF THIS PROJECT SHOULD DEMONSTRATE A SCHEME IN WHICH THE ANTICARCINOGENIC PROTEASE INHIBITOR I CAN BE PRODUCED AT COSTS 5-10 TIMES LOWER THAN COMMERCIALLY AVAILABLE PRODUCT. PHASE II OF THE PROJECT WILL MOVE THE PREPARATION OF THE INHIBITOR INTO A DEMONSTRABLE PILOT PHASE AND WILL ALSO BE USED TO CREATE OTHER TRANSGENIC TOMATO PLANTS CONTAINING OTHER INHIBITORS. IT IS ANTICIPATED THAT THE PRODUCTION OF AT LEAST SOME OF THESE WILL BE MOVED TO PILOT SCALE IN PHASE II.